1. Home
  2. ATNM vs ONCY Comparison

ATNM vs ONCY Comparison

Compare ATNM & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATNM
    SELLHOLDBUYas of a day ago
  • ONCY
    SELLHOLDBUYas of 4 hours ago
  • Stock Information
  • Founded
  • ATNM 2000
  • ONCY 1998
  • Country
  • ATNM United States
  • ONCY Canada
  • Employees
  • ATNM N/A
  • ONCY N/A
  • Industry
  • ATNM Biotechnology: Pharmaceutical Preparations
  • ONCY Pharmaceuticals and Biotechnology
  • Sector
  • ATNM Health Care
  • ONCY Health Care
  • Exchange
  • ATNM Nasdaq
  • ONCY Nasdaq
  • Market Cap
  • ATNM 46.5M
  • ONCY 53.6M
  • IPO Year
  • ATNM N/A
  • ONCY 1999
  • Fundamental
  • Price
  • ATNM $1.49
  • ONCY $0.54
  • Analyst Decision
  • ATNM Strong Buy
  • ONCY Strong Buy
  • Analyst Count
  • ATNM 4
  • ONCY 4
  • Target Price
  • ATNM $8.75
  • ONCY $4.00
  • AVG Volume (30 Days)
  • ATNM 1.3M
  • ONCY 224.8K
  • Earning Date
  • ATNM 04-25-2025
  • ONCY 03-07-2025
  • Dividend Yield
  • ATNM N/A
  • ONCY N/A
  • EPS Growth
  • ATNM N/A
  • ONCY N/A
  • EPS
  • ATNM N/A
  • ONCY N/A
  • Revenue
  • ATNM $81,000.00
  • ONCY N/A
  • Revenue This Year
  • ATNM $138.42
  • ONCY N/A
  • Revenue Next Year
  • ATNM $16,957.05
  • ONCY N/A
  • P/E Ratio
  • ATNM N/A
  • ONCY N/A
  • Revenue Growth
  • ATNM N/A
  • ONCY N/A
  • 52 Week Low
  • ATNM $1.03
  • ONCY $0.55
  • 52 Week High
  • ATNM $10.24
  • ONCY $1.53
  • Technical
  • Relative Strength Index (RSI)
  • ATNM 59.52
  • ONCY 26.43
  • Support Level
  • ATNM $1.66
  • ONCY $0.58
  • Resistance Level
  • ATNM $2.41
  • ONCY $0.65
  • Average True Range (ATR)
  • ATNM 0.22
  • ONCY 0.03
  • MACD
  • ATNM 0.05
  • ONCY -0.00
  • Stochastic Oscillator
  • ATNM 37.60
  • ONCY 1.36

Stock Price Comparison Chart: ATNM vs ONCY

ATNM
ONCY
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025April0246810121416ATNM VS ONCY

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About ONCY Oncolytics Biotech Inc.

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use